Jude Samulski, AskBio

Bay­er and AskBio ex­pand grand gene ther­a­py am­bi­tions with new Parkin­son's pro­gram, top sci­en­tist

It on­ly took 20 years, but Jude Samul­s­ki is fi­nal­ly turn­ing AskBio in­to a gene ther­a­py be­he­moth in the hills of North Car­oli­na.

The now Bay­er-owned biotech an­nounced Thurs­day they were bring­ing over the clin­i­cal team from Brain Neu­rother­a­py Bio, com­plet­ing a buy­out tipped in De­cem­ber and adding clin­i­cal pro­grams in Parkin­son’s and mul­ti­ple sys­tem at­ro­phy to an al­ready large pipeline.

AskBio launched Brain­Neu­Bio in 2018, a move con­sis­tent with Samul­s­ki’s long-run­ning strat­e­gy of spin­ning out promis­ing pro­grams, which led to the Bam­boo Ther­a­peu­tics and Pfiz­er’s Duchenne Gene Ther­a­py pro­gram, as well as a he­mo­phil­ia pro­gram now owned by Take­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.